Dosing of chemoprophylaxis for venous thromboembolism in patients with a body mass index greater than 30 kg/m²
South Australian Journal of Medicine · 2026
DOI: 10.66861/lvqq7562 ↗Kurz gefasst
Fachartikel in der Zeitschrift South Australian Journal of Medicine, 2026. Verfasst von Claire Jones.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Anticoagulant dosing guidelines for chemoprophylaxis of a venous thromboembolism (VTE) do not consider body mass index (BMI). Patients who have a higher BMI are potentially underdosed when prescribed standard dosing of anticoagulant, increasing their risk of VTE.
Aim
This study aimed to audit prescribing practices for VTE chemoprophylaxis in a tertiary hospital and to investigate whether clinicians prescribe increased enoxaparin or heparin doses for patients who have an increased BMI.
Methods
A retrospective clinical audit was conducted by obtaining a data extract from the electronic medical record (EMR) for patients with an increased BMI greater than 30.0 kg/m2 who were prescribed VTE chemoprophylaxis and who had been admitted to the medical and surgical units of a tertiary hospital over a three-month period in 2019. Patient demographics, admission diagnosis or surgery type, and dose and duration of chemoprophylaxis were collected. The EMR was reviewed to determine whether patients were readmitted to hospital within three months of discharge.
Results
During the three-month audit window, 307 patients had a BMI greater than 30.0 kg/m2 and were prescribed VTE chemoprophylaxis. Only two of the 307 patients (0.65%; both with a BMI greater than 50.0 kg/m2) had a dose increase above the guideline-recommended dose. For the remainder of the cohort, enoxaparin 20 mg and 40 mg daily were prescribed in 15% (n = 46) and 72.6% (n = 223) of patients, respectively, and subcutaneous heparin 5000 units twice daily was prescribed in 11.7% (n = 36) of patients. The three-month hospital readmission rate for all causes was 20.8% (64 of 307). There were no readmissions for VTE.
Conclusion
The audit identified that clinicians were prescribing VTE chemoprophylaxis doses according to local guidelines, and that doses were not routinely increased for patients with an increased BMI.
Zitieren
APA
Jones, C. (2026). Dosing of chemoprophylaxis for venous thromboembolism in patients with a body mass index greater than 30 kg/m². South Australian Journal of Medicine. https://doi.org/10.66861/lvqq7562
Vancouver
Jones C. Dosing of chemoprophylaxis for venous thromboembolism in patients with a body mass index greater than 30 kg/m². South Australian Journal of Medicine. 2026. doi:10.66861/lvqq7562
BibTeX
@article{Jones2026,
author = {Jones, Claire},
title = {Dosing of chemoprophylaxis for venous thromboembolism in patients with a body mass index greater than 30 kg/m²},
journal = {South Australian Journal of Medicine},
year = {2026},
doi = {10.66861/lvqq7562}
}
EUVIMED